Pegsunercept is a drug for the treatment of rheumatoid arthritis. As of January 2010 Phase II clinical trials have been completed. It is being developed by Amgen.Similarly to etanercept pegsunercept is a soluble tumor necrosis factor receptor. Pegsunercept is a PEGylated protein.
This page contains content from the copyrighted Wikipedia article "Pegsunercept"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.